Tag: M.W:100-200

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.294-90-6,1,4,7,10-Tetraazacyclododecane,as a common compound, the synthetic route is as follows.

Di-tert-butyl dicarbonate (16.5 g, 0.076 mol) in chloroform (100 mL) was added dropwise to a chilled mixture of 1 ,4,7,10-tetraazacyclododecane (5.0 g, 0.029 mol) and diisopropylamine (15 mL, 0.087 mol) in chloroform (200 mL) over a period of three hours. The reaction was then stirred overnight under an atmosphere of nitrogen. The reaction was concentrated, brought up in ethyl acetate (600 mL) and washed with saturated sodium bicarbonate (200 mL), followed by one wash of monobasic potassium phosphate (200 mL of 1 M) and brine (200 mL). The ethyl acetate was dried over sodium sulfate, filtered and concentrated. The crude reaction was purified using flash chromatography (4:1 ethyl acetate :hexanes) to yield a white solid (7.84 g, 57%). 1H NMR (400 MHz, CDCI3) delta 3.67-3.52 (br, 4H), 3.46-3.14 (m, 8H), 2.88-2.72 (br, 4H), 1 .44 (s, 9H), 1 .42 (s, 18H); 13C NMR (100 MHz, CDCI3) delta 155.4, 79.2, 79.1 , 50.8, 49.3, 49.3, 48.7, 45.8, 44.8, 28.5, 28.3; LRMS (ESI): m/z [M+H]+ calc’d for C23H45N406+ 473.33, found 473.33., 294-90-6

The synthetic route of 294-90-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO; GUNNING, Patrick Thomas; DA SILVA, Sara R.; PAIVA, Stacey-Lynn; LUKKARILA, Julie Lynn; WO2015/179955; (2015); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

13910-48-0, N1-Benzylpropane-1,3-diamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: Pyrazolone 1b (643 mg, 1.88 mmol) was dissolved in CH3CN (10 mL) and amine 2N-benzylpropane-1,3-diamine was added at 0 C under N2. The reaction mixture was stirred at 0 C for 3 h and monitored by LC-MS showing 40% of starting material left. Then DIPEA (two drops) was added and the mixture was stirred at RT for 1 h: LC-MS showed completely conversion of starting material into desired product. The solvent was concentrated in vacuo until dryness. The residue was dissolved in ethylacetate (10 mL), washed with saturated NaHCO3 solution (5 mL * 2), dried over Na2SO4 and concentrated. The crude product was used in the following step without further manipulation (530 mg, 71% yield, 86% HPLC purity, LC-MS (M+H)+: 453.4).

13910-48-0, 13910-48-0 N1-Benzylpropane-1,3-diamine 83811, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Gaggini, Francesca; Laleu, Benoit; Orchard, Mike; Fioraso-Cartier, Laetitia; Cagnon, Laurne; Houngninou-Molango, Sophie; Gradia, Angelo; Duboux, Guillaume; Merlot, Cedric; Heitz, Freddy; Szyndralewiez, Cedric; Page, Patrick; Bioorganic and Medicinal Chemistry; vol. 19; 23; (2011); p. 6989 – 6999;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

581-50-0,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.581-50-0,2,3′-Bipyridine,as a common compound, the synthetic route is as follows.

General procedure: Complexes 3-6 were prepared according to the following procedure:after stirring for 1 h a methanolic solution (20 mL) ofHindo (0.4 mmol, 143 mg) and KOH (0.4 mmol, 23 mg), the solutionwas added to a methanolic solution (5 mL) of NiCl26H2O(0.2 mmol, 47 mg) simultaneously with a methanolic solution(5 mL) of bipy (0.2 mmol, 31 mg) for 3, bipyam (0.2 mmol,34 mg) for 4, phen (0.2 mmol, 36 mg) for 5 and Hpko (0.4 mmol,79 mg) for 6. The resultant solution was stirred for 30 min andwas left to evaporate slowly. Light-green microcrystalline product of complex 4 (105 mg, 55%) was collected after two weeks. Anal. Calc. for [Ni(indo)2(bipyam)], 4 (C48H39Cl2N5NiO8) (MW = 943.48) C, 61.11; H, 4.17; N, 7.42 found: C, 60.98; H, 4.04; N, 7.31%. IR (KBr disk): numax, cm-1; nu(C=O)indo, 1678(vs); nuasym(CO2), 1590 (vs); nusym(CO2), 1414 (s); Deltanu(CO2) = 176 cm-1; rho(C-H)bipyam: 765 (m). UV-Vis: as Nujol mull, lambda(nm): 995 (sh), 657, 418 (sh), 324, 308 (sh); in DMSO, lambda(nm) (epsilon, M-1cm-1): 997 (sh) (20), 662 (60), 424 (sh) (230), 324 (12740), 293 (17020); 10Dq = 10030 cm-1, B = 573 cm-1, 10Dq/B = 17.5. mueff at room temperature = 3.25 BM. Soluble in CHCl3 and DMSO (LambdaM = 5 S¡¤cm2¡¤mol-1, in 1 mM DMSO solution).

581-50-0 2,3′-Bipyridine 11389, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Perontsis, Spyros; Tialiou, Alexia; Hatzidimitriou, Antonios G.; Papadopoulos, Athanasios N.; Psomas, George; Polyhedron; vol. 138; (2017); p. 258 – 269;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5, D-Prolinamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

62937-45-5, A solution of 5-(4-chlorophenyl)-2-{ [l-(2-chloropyridin-3-yl) H-l,2,4-triazol-3-yl]methyl}-4- [(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-l,2,4-triazol-3-one (Example 44A; 70.0 mg, 140 muiotaetaomicron) in ethanol (280 mu) was treated with D-prolinamide (160 mg, 1.40 mmol) and stirred overnight at reflux. The reaction mixture was diluted with methanol and purified by preparative HPLC (Method 4) affording 56.3 mg (70 % of th.) of the title compound. LC-MS (Method 2): Rt = 1.52 min; MS (ESIpos): m/z = 578.2 [M+H]+ -NMR (400 MHz, DMSO-d6) delta [ppm]: 8.80 (s, 1H), 8.19 (dd, 1H), 7.79-7.52 (m, 5H), 7.06 (br s, 1H), 6.95-6.71 (m, 3H), 5.18-5.02 (m, 2H), 4.48-4.21 (m, 2H), 4.06-3.78 (m, 2H), 2.77-2.58 (m, 2H), 2.04-1.87 (m, 1H), 1.75-1.42 (m, 3H).

62937-45-5 D-Prolinamide 447554, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; BAYER AKTIENGESELLSCHAFT; BAYER PHARMA AKTIENGESELLSCHAFT; COLLIN-KROePELIN, Marie-Pierre; KOLKHOF, Peter; NEUBAUER, Thomas; FUeRSTNER, Chantal; POOK, Elisabeth; WITTWER, Matthias, Beat; LUSTIG, Klemens; TINEL, Hanna; LINDNER, Niels; SCHIRMER, Heiko; (449 pag.)WO2019/81307; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10581-12-1,Tetramethylammonium acetate,as a common compound, the synthetic route is as follows.

General procedure: A solution of H3F3ST (300mg, 0.39mmol) dissolved in 6mL of anhydrous dimethylacetamide (DMA) was treated with solid NaH (28mg, 1.2mmol). The mixture was stirred until gas evolution ceased. Fe(OAc)2 (68mg, 0.39mmol) and NMe4OAc (52mg, 0.39mmol), were added to the cloudy white reaction, and the solution was stirred. After 3h, 5mL of Et2O was added to the yellow solution to aid the precipitation of NaOAc. The reaction mixture was filtered through a medium porosity glass-fritted funnel to remove the insoluble species and the filtrate was dried under vacuum. The resulting pale yellow solid was redissolved in 5mL of acetonitrile (MeCN), stirred for 20min, and filtered using a fine porosity glass-fritted funnel. The filtrate was concentrated under vacuum to ca. 1mL and treated with Et2O (10mL) then pentane (40mL) to precipitate a pale yellow solid. The pale yellow solid was collected on a medium porosity glass-fritted funnel and dried under vacuum to give 182mg (91%) of product., 10581-12-1

10581-12-1 Tetramethylammonium acetate 82741, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Lau, Nathanael; Ziller, Joseph W.; Borovik; Polyhedron; vol. 85; (2015); p. 777 – 782;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.10581-12-1,Tetramethylammonium acetate,as a common compound, the synthetic route is as follows.

To a solution of compound 3 (20g, 42.8mmol, 1.0eq) in Toluene (200mL) was added tetra methyl ammonium acetate (14.3g, 54.8mmol, 1.28eq) at rt. The mixture was heated to reflux for 16h. TLC analysis indicated formation of a polar spot. Then the reaction mass was extracted with EtOAc (2 X 200m L) and washed with water (2 X 100ml_) and brine (2 X 100ml_). The organic layer was dried under reduced pressure. The residue (40 g) was taken up with 80ml_ of 2-prpoanol. The mixture was stirred at 0C for 30 mins and the resulting Crystalline product was collected under dried under vaccum to give compound 4 (12 g, 68%) as a pale yellow color Solid. LCMS: 79.34% with m/z 356.24 (M+H):

10581-12-1, As the paragraph descriping shows that 10581-12-1 is playing an increasingly important role.

Reference£º
Patent; ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR); AL-AWAR, Rima; ISAAC, Methvin; CHAU, Anh My; MAMAI, Ahmed; WATSON, Iain; PODA, Gennady; SUBRAMANIAN, Pandiaraju; WILSON, Brian; UEHLING, David; PRAKESCH, Michael; JOSEPH, Babu; MORIN, Justin-Alexander; (441 pag.)WO2019/153080; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4062-60-6,4062-60-6, N1,N2-Di-tert-butylethane-1,2-diamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: Toluene (5 mL), secondary diamine (2a,b or 4-c) (1 mmol), paraformaldehyde or 4-fluorobenzaldehyde (2 mmol), alpha,omega-diacetylene (2 mmol), and CuCl (10 mol.%, 0.1 mg) were placed under argon into a Schlenk flask (10 mL) mounted on a magnetic stirrer, and the mixture was stirred for 8 h at 100 C under argon atmosphere.The resulting mixture was cooled, filtered through a layer ofsilica gel, dried over Na2SO4. The solvent was evaporated. The product was purified by column chromatography, the eluent is indicated in the description of the compound.

4062-60-6 N1,N2-Di-tert-butylethane-1,2-diamine 77680, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Article; Khabibullina; Zaynullina; Tyumkina; Yanybin; Ibragimov; Russian Chemical Bulletin; vol. 68; 7; (2019); p. 1407 – 1413; Izv. Akad. Nauk, Ser. Khim.; 7; (2019); p. 1407 – 1413,7;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.4730-54-5,1,4,7-Triazacyclononane,as a common compound, the synthetic route is as follows.

Example 2 Preparation of 1,4-bis (trifluoroacetyl)-1,4,7-triazacyclononane 1,4,7-triazacyclononane (115.0 mg, 0.89 mmol) was dissolved in MeOH (2.0mL). To this clear solution was added NEt3 (0.13 mL, 0.89 mmol) in one portion, followed by ethyl trifluoroacetate (0.43 mL, 13.56 mmol) during a period of 5 minutes. Stirring was continued under N2 for 15 hours. Volatiles were then removed by rotavapor. The residue was dissolved in the minimum amount of CH2Cl2 (~2.0mL) and passed through a short silica gel pad, eluted with 100% EtOAc. The eluent was concentrated to give the product as a white solid (267.0 mg, 94%). 1H NMR (300 MHz, CDCl3): delta4.04-3.95 (multiplet, 2 H), 3.80-3.72 (multiplet, 2 H), 3.50-3.40 (multiplet, 4 H), 3.0-2.90 (multiplet, 4 H), 1.59 (singlet, 1 H). Mass calculated for C10H13F6N3O2 321.2, found M+1 322.1.

4730-54-5, The synthetic route of 4730-54-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Giandomenico, Christen M.; Yang, Wen; US2002/58807; (2002); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.16011-97-5,N1,N4-Dimethylbutane-1,4-diamine,as a common compound, the synthetic route is as follows.

A mixture of 2-chloro-3-nitropyridin-4-amine (LXXXIII) (1.0 g, 5.76 mmol) and DIPEA (1.0 mL, 5.76 mmol) in THF (20 mL) was stirred at room temperature for 1 h. The reaction was concentrated to dryness and the residue was taken up in EtOAc and the organic layer was washed with 2 x water then 1 x brine solution. The organic layers were then separated and dried (MgSO4) before concentration to dryness to obtain N2-methyl-N2-(4- (methylamino)butyl)-3-nitropyridine-2,4-diamine (LXXXIV) (160 mg, 6.32 mmol, 109.6% yield) as dark brown gum which was used for next step without purification. ESIMS found for C11H19N5O2 m/z 254.1 (M+H).

16011-97-5, The synthetic route of 16011-97-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; SAMUMED, LLC; KC, Sunil Kumar; MITTAPALLI, Gopi Kumar; CHIRUTA, Chandramouli; HOFILENA, Brian Joseph; (128 pag.)WO2019/241540; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

16011-97-5, N1,N4-Dimethylbutane-1,4-diamine is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

(1) Weigh 58g of hydroxyethyl acrylate in the three-necked flask, was added 50mL of methylene chloride, 90.9 g of triethylamine was added, the ice bath until the temperature drops 0 C, and after stabilization, dropwise addition of 62.7g of methacryloyl chloride, dropping control, completion of the dropwise within 120min, after completion of the dropwise addition, reaction was continued under ice-bath 3h, warmed to room temperature, the reaction was continued 24h; after completion of the reaction, stirring was stopped, the resulting solid salt was removed by filtration, and the filtrate was added to a separatory funnel, washed with deionized water 2-3 times, adding an appropriate amount of anhydrous sodium sulfate 24h, filtered, and the solvent methylene chloride was removed by rotary evaporation; (2) the reaction product weighed step (1) of 92 g, the ice bath was added dropwise N,N’-dimethyl-1,4-butanediamine 58g, addition was complete within 25min, warmed to 60 C, after the reaction 4h, 47.5g of methyl bromide was added dropwise to the reaction system, the reaction was continued 3H; (3) cooling to 40 C, deionized water was added to the reaction system to prepare a 40wt% aqueous solution.

16011-97-5, As the paragraph descriping shows that 16011-97-5 is playing an increasingly important role.

Reference£º
Patent; Anqing Bei Hua Da Science And Technology Yuan Co., Ltd.; Nie Jun; Li Sanbao; Zhu Xiaoqun; (7 pag.)CN109651296; (2019); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI